RT Journal Article
SR Electronic
T1 Warfarin-associated intracranial hemorrhage during anticoagulation therapy
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2401
VO 44
IS Suppl 58
A1 So-My Koo
A1 Yang-Ki Kim
A1 Soo-taek Uh
A1 Ki-Up Kim
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2401.abstract
AB The incidence of venous thromboembolism including pulmonary embolism and deep vein thrombosis is increasing in Korea. As the use of vitamin K antagonists is increased, the risk of anticoagulant-related intracranial hemorrhage(ICH) is emphasized. Anticoagulant-related ICH in patients with anticoagulation therapy is approximately 0.2% per year occurred. There is no study about anticoagulant-related ICH in Korea. We retrospectively reviewed the records of ICH patients at Soonchunhyang University Hospital, Seoul, Korea, from 1 January 2004 to 31 December 2012. We divided into two groups depending on whether the administration of warfarin. The primary outcome was 30-day mortality. Secondary outcomes were the ways for reversal of hemorrhage and overall outcomes. ICH hopitalizations were in 3,232 patients. Except exclusion criteria (n=721), among total 2,511 patients, the warfarin-associated ICH occurred in 50 patients(2.0%). The 30-day mortality in warfarin-associated ICH patients was 40% compared with 13% in non-warfarin-associated ICH patients. The ways for reversal of hemorrhage were vitamin K(53% vs 8.3%,p<0.0001), fresh frozen plasma(6.0% vs 2.1%,p=0.0947),or cryoprecipitate(0% vs 0.2%,p=1.000) in two groups(warfarin-associated ICH vs non-warfarin-associated ICH). The rates of operation were not different significantly between two groups (operation:38% vs 26.7%,p=0.733). There were significant differences on the rates recurrent ICH and overall mortality(recurrent ICH: 8% vs 2%,p=0.0199; overall mortality: 40% vs 13.3%,p<0.0001). Warfarin-associated ICH patients have higher 30-day mortality compared with non-warfarin-associated ICH patients.